Related Experiment Videos
Effects of basic fibroblast growth factor in retinal ischemia
C Zhang1, K Takahashi, T T Lam
1Georgiana Dvorak Theobald Ophthalmic Pathology Laboratory, Department of Ophthalmology and Visual Sciences, College of Medicine, University of Illinois at Chicago 60612.
Investigative Ophthalmology & Visual Science
|July 1, 1994
Summary
Basic fibroblast growth factor (bFGF) partially protected retinal ganglion cells (RGCs) from ischemic injury in rats. This neuroprotective effect was observed through reduced cell death and preserved retinal layer thickness after ischemia.
Area of Science:
- Neuroscience
- Ophthalmology
- Regenerative Medicine
Background:
- Basic fibroblast growth factor (bFGF) is crucial for neuronal survival and has previously shown potential in retinal cell protection.
- Retinal ischemia, a condition leading to neuronal loss, poses a significant challenge in ophthalmology.
Purpose of the Study:
- To evaluate the efficacy of bFGF in preventing neuronal loss in a rat model of retinal ischemia.
- To assess the neuroprotective effects of bFGF on retinal ganglion cells (RGCs) and other inner retinal layers following ischemic injury.
Main Methods:
- Retinal ischemia was induced in rats by increasing intraocular pressure.
- Basic fibroblast growth factor (bFGF) was administered into the anterior chamber at the time of ischemia induction.
- Vehicle control (heparin in phosphate-buffered saline) was administered to a separate group of rats.
Main Results:
- bFGF treatment significantly reduced the severity of RGC necrosis and thinning of inner retinal layers compared to controls.
- Morphometric analysis revealed higher RGC counts and inner retinal layer thickness in bFGF-treated eyes 7 days post-reperfusion.
- Similar protective effects were observed at 14 days, with notable preservation of RGCs and retinal structures.
Conclusions:
- Basic fibroblast growth factor (bFGF) demonstrates partial neuroprotection for retinal ganglion cells (RGCs) against ischemic damage.
- These findings suggest bFGF as a potential therapeutic agent for conditions involving retinal ischemia and neuronal loss.